Implantable pump for long-term chemotherapy administration via the hepatic artery: Has it fulfilled its promise?

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4528-4529

  Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; COLORECTAL CANCER; COST; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LONG TERM CARE; MINIPUMP; NOTE; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; SURGEON; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 53749097262     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.0117     Document Type: Note

References (11)

1. Weiss GR, Garnick MB, Osteen RT, et al: Long term hepatic arterial infusion of 5-fluorodeoxuridine for liver metastasis using an implantable infusion pump. J Clin Oncol 1:337-334, 1983
2. Ensminger N, Niederhuber J, Dakhil S, et al: Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393-400, 1981
3. Barone RM, Byfield JE, Goldfarb PB, et al: Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastasis. Cancer 50:850-862, 1982
4. Kemeny N, Conti JA, Cohen A, et al: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994
5. Allen PJ, Nissan A, Picon AI, et al: Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg 201:57-65, 2005
6. Mocellin S, Pilati P, Lise M, et al: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol 25:5649-5654, 2007
7. Kemeny N, Brown K, Covey A, et al: Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17:1214-1224, 2006
8. Reid T, Galanis E, Abbruzzese J, et al: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 8:1618-1626, 2001
9. Kemeny N, Niedzwiecki D, Hollis D, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395-1403, 2006
10. Kemeny N, Jarnagin W, Paty P, et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888-4896, 2005
11. Gallagher DJ, Capanu M, Raggio G, et al: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis. Ann Oncol 18:1995-1999, 2007